Hospital Length of Stay: Does Rivaroxaban Reduce Inpatient Stay Compared to Warfarin Among Patients With Non-Valvular Atrial Fibrillation?

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.598
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Comparative Pharmacoeconomic Analysis of Rivaroxaban and Warfarin Usage in Patients With Non-Valvular Atrial Fibrillation

Jounal of arrhythmology
2020English

Under-Use of Warfarin for Patients With Non-Valvular Atrial Fibrillation in Japan

Internal Medicine
Internal MedicineMedicine
2004English

Impact of Rivaroxaban Compared With Warfarin on the Coagulation Status in Japanese Patients With Non-Valvular Atrial Fibrillation: A Preliminary Analysis of the Prothrombin Fragment 1+2 Levels

Journal of Cardiology
Cardiovascular MedicineCardiology
2015English

Impact of New Onset In-Hospital Atrial Fibrillation on Length of Stay and Mortality

Heart Lung and Circulation
Respiratory MedicinePulmonaryCardiovascular MedicineCardiology
2017English

Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Yearbook of Cardiology
2012English

Effect and Risk of Novel Oral Anticoagulants Versus Warfarin in Patients With Non-Valvular Atrial Fibrillation

Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

Primary and Secondary Prevention of Stroke and Systemic Embolism With Rivaroxaban in Patients With Non-Valvular Atrial Fibrillation

Heart and Vessels
Cardiovascular MedicineCardiology
2018English

Suboptimal Oral Anticoagulant Treatment Among Chinese Non-Valvular Atrial Fibrillation Patients: The Nanchang Atrial Fibrillation Project

Archives of Medical Science
Medicine
2016English

Factors Affecting Length of Hospital Stay.

BMJ
1978English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy